Article: Positive two-year data for ALK-Abello's Grazax.(preventing grass pollen allergy)(Brief article)

Danish drugmaker ALK-Abello has reported strong top-line results from the second treatment year in a long-term study of Grazax, its tablet-based vaccine against grass pollen allergy. According to the firm, the agent showed increased clinical effect and immunological changes in the second treatment year, supporting expectations of a progressive effect with long-term treatment.

The data, which were presented at the annual conference of the American Academy of Allergy, Asthma and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!